Drugs / andrographolide sulfonate
andrographolide sulfonate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02913118 | Jul 2016 → Jan 2019 | — | Qingfeng Pharmaceutical Group | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03132623 Comparator | Dec 2016 → Dec 2017 | bronchitis | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03134443 Comparator | Dec 2016 → Dec 2017 | acute tonsillitis | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03132610 Comparator | Dec 2016 → Dec 2017 | chronic bronchitis | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Andrographolide Sulfonate | “To investigate the effect and safety of Andrographolide Sulfonate (AS) Injection for adjunctive treatment of non-severe community-acquired pneumonia (CAP) in adults.” PMID 41489779 ↗ Jan 2026 |
| Known as | Andrographolid Sulfonate Injection | “Andrographolid Sulfonate Injection (AS Injection)” NCT02913118 ↗ |
| Known as | AS Injection | “To investigate the effect and safety of Andrographolide Sulfonate (AS) Injection for adjunctive treatment of non-severe community-acquired pneumonia (CAP) in adults.” PMID 41489779 ↗ Jan 2026 |
| Route | Intravenous | “Patients received either intravenous AS Injection (500 mg once per day) or placebo for 5 d.” PMID 41489779 ↗ Jan 2026 |